Drug resistance mutation frequency comparison, 2000–2005 vs. 2006–2015, for Brazil. by Santiago Avila-Rios (3160959)

Subjects:

Characteristics of participants in the surveys included in the present review per region. by Santiago Avila-Rios (3160959)

Subjects:

PDR meta-analysis for the LAC region, 2000–2015. by Santiago Avila-Rios (3160959)

Subjects:

Drug resistance mutation frequency comparison, 2000–2005 vs. 2006–2015, for the Caribbean. by Santiago Avila-Rios (3160959)

Subjects:

Drug resistance mutation frequency comparison, 2000–2005 vs. 2006–2015, for the Southern Cone. by Santiago Avila-Rios (3160959)

Subjects:

HIV subtype distribution in Brazil. by Santiago Avila-Rios (3160959)

Subjects:

Drug resistance mutation frequency comparison, 2000–2005 vs. 2006–2015, for the Andean region. by Santiago Avila-Rios (3160959)

Subjects:

HIV subtype distribution in the LAC region. by Santiago Avila-Rios (3160959)

Subjects:

Publications on HIV PDR in the Andean Region, 2000–2015. by Santiago Avila-Rios (3160959)

Subjects:

Publications on HIV PDR in Brazil, 2000–2015. by Santiago Avila-Rios (3160959)

Subjects:

Publications on HIV PDR in the Mesoamerican Region, 2000–2015. by Santiago Avila-Rios (3160959)

Subjects:

Drug resistance mutation frequency comparison, 2000–2005 vs. 2006–2015, for the Mesoamerican region. by Santiago Avila-Rios (3160959)

Subjects:

Publications on HIV PDR in the Southern Cone, 2000–2015. by Santiago Avila-Rios (3160959)

Subjects:

Drug resistance mutation frequency comparison, 2000–2005 vs. 2006–2015, for the whole LAC region. by Santiago Avila-Rios (3160959)

Subjects:

Publications on HIV PDR in the Caribbean, 2000–2015. by Santiago Avila-Rios (3160959)

Subjects:

Surveillance of HIV Transmitted Drug Resistance in Latin America and the Caribbean: A Systematic Review and Meta-Analysis by Santiago Avila-Rios (3160959)

Subjects:

Knockdown of VGLUT1 results in a concomitant decrease in synaptic expression of synapsin and synaptophysin. by Corbett T. Berry (296520)

“…(<b>E</b>) Synaptophysin was not decreased in KD neurons co-expressing VGLUT1 (<i>V1</i>, VGLUT1 expressing neurons; p = 0.940; n = 244 and 96 puncta from 13 and 9 axons for SCR and V1, respectively, from a representative experiment. …”

<i>csrnp1a</i> knockdown decreases the number of blood cells in circulation. by Jaime Espina (106906)

“…(I) qPCR with primers located in exon 2 and 3 of 24 hpf control embryos (C) and splicing morphants injected with two concentrations, 2,5 and 5 ng per embryo, showing the relative expression of <i>csrnp1a</i> message, which decreases significantly in a dose-dependent manner (t student p<0,01).…”

A brief course of RAP treatment decreases markers of proliferation and increases markers of differentiation. by Karin M. Hardiman (555189)

“…(D) Alcian blue staining shows loss of most of the differentiated goblet cells in mouse polyps and RAP restore the goblet cell differentiation. (E) Immunostaining shows increased Sox9 (a cell fate marker) expression in polyps and RAP decreased the number of cells expressing Sox9. …”

Healthspan decreases in response to cell-associated factor LPS in a dose-dependent manner. by Gabriel M. Moore (8566113)